Safety of nanoparticles in medicine

Joy Wolfram, Motao Zhu, Yong Yang, Jianliang Shen, Emanuela Gentile, Donatella Paolino, Massimo Fresta, Guangjun Nie, Chunying Chen, Haifa Shen, Mauro Ferrari, Yuliang Zhao

Research output: Contribution to journalReview article

85 Citations (Scopus)

Abstract

Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes. During the past two decades, a growing number of nanomedicines have received regulatory approval and many more show promise for future clinical translation. In this context, it is important to evaluate the safety of nanoparticles in order to achieve biocompatibility and desired activity. However, it is unwarranted to make generalized statements regarding the safety of nanoparticles, since the field of nanomedicine comprises a multitude of different manufactured nanoparticles made from various materials. Indeed, several nanotherapeutics that are currently approved, such as Doxil and Abraxane, exhibit fewer side effects than their small molecule counterparts, while other nanoparticles (e.g. metallic and carbon-based particles) tend to display toxicity. However, the hazardous nature of certain nanomedicines could be exploited for the ablation of diseased tissue, if selective targeting can be achieved. This review discusses the mechanisms for molecular, cellular, organ, and immune system toxicity, which can be observed with a subset of nanoparticles. Strategies for improving the safety of nanoparticles by surface modification and pretreatment with immunomodulators are also discussed. Additionally, important considerations for nanoparticle safety assessment are reviewed. In regards to clinical application, stricter regulations for the approval of nanomedicines might not be required. Rather, safety evaluation assays should be adjusted to be more appropriate for engineered nanoparticles.

Original languageEnglish (US)
Pages (from-to)1671-1681
Number of pages11
JournalCurrent Drug Targets
Volume16
Issue number14
StatePublished - 2015
Externally publishedYes

Fingerprint

Nanoparticles
Medicine
Nanomedicine
Medical nanotechnology
Safety
Toxicity
Metal Nanoparticles
Immunologic Factors
Therapeutic Uses
Immune system
Ablation
Biocompatibility
Immune System
Carbon
Surface treatment
Assays
Tissue
Molecules

Keywords

  • Nanomedicine
  • Nanoparticle
  • Nanosafety
  • Nanotoxicity
  • Safety
  • Toxicity

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Wolfram, J., Zhu, M., Yang, Y., Shen, J., Gentile, E., Paolino, D., ... Zhao, Y. (2015). Safety of nanoparticles in medicine. Current Drug Targets, 16(14), 1671-1681.

Safety of nanoparticles in medicine. / Wolfram, Joy; Zhu, Motao; Yang, Yong; Shen, Jianliang; Gentile, Emanuela; Paolino, Donatella; Fresta, Massimo; Nie, Guangjun; Chen, Chunying; Shen, Haifa; Ferrari, Mauro; Zhao, Yuliang.

In: Current Drug Targets, Vol. 16, No. 14, 2015, p. 1671-1681.

Research output: Contribution to journalReview article

Wolfram, J, Zhu, M, Yang, Y, Shen, J, Gentile, E, Paolino, D, Fresta, M, Nie, G, Chen, C, Shen, H, Ferrari, M & Zhao, Y 2015, 'Safety of nanoparticles in medicine', Current Drug Targets, vol. 16, no. 14, pp. 1671-1681.
Wolfram J, Zhu M, Yang Y, Shen J, Gentile E, Paolino D et al. Safety of nanoparticles in medicine. Current Drug Targets. 2015;16(14):1671-1681.
Wolfram, Joy ; Zhu, Motao ; Yang, Yong ; Shen, Jianliang ; Gentile, Emanuela ; Paolino, Donatella ; Fresta, Massimo ; Nie, Guangjun ; Chen, Chunying ; Shen, Haifa ; Ferrari, Mauro ; Zhao, Yuliang. / Safety of nanoparticles in medicine. In: Current Drug Targets. 2015 ; Vol. 16, No. 14. pp. 1671-1681.
@article{1ab9314b9bd745808e3455beb893a5e5,
title = "Safety of nanoparticles in medicine",
abstract = "Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes. During the past two decades, a growing number of nanomedicines have received regulatory approval and many more show promise for future clinical translation. In this context, it is important to evaluate the safety of nanoparticles in order to achieve biocompatibility and desired activity. However, it is unwarranted to make generalized statements regarding the safety of nanoparticles, since the field of nanomedicine comprises a multitude of different manufactured nanoparticles made from various materials. Indeed, several nanotherapeutics that are currently approved, such as Doxil and Abraxane, exhibit fewer side effects than their small molecule counterparts, while other nanoparticles (e.g. metallic and carbon-based particles) tend to display toxicity. However, the hazardous nature of certain nanomedicines could be exploited for the ablation of diseased tissue, if selective targeting can be achieved. This review discusses the mechanisms for molecular, cellular, organ, and immune system toxicity, which can be observed with a subset of nanoparticles. Strategies for improving the safety of nanoparticles by surface modification and pretreatment with immunomodulators are also discussed. Additionally, important considerations for nanoparticle safety assessment are reviewed. In regards to clinical application, stricter regulations for the approval of nanomedicines might not be required. Rather, safety evaluation assays should be adjusted to be more appropriate for engineered nanoparticles.",
keywords = "Nanomedicine, Nanoparticle, Nanosafety, Nanotoxicity, Safety, Toxicity",
author = "Joy Wolfram and Motao Zhu and Yong Yang and Jianliang Shen and Emanuela Gentile and Donatella Paolino and Massimo Fresta and Guangjun Nie and Chunying Chen and Haifa Shen and Mauro Ferrari and Yuliang Zhao",
year = "2015",
language = "English (US)",
volume = "16",
pages = "1671--1681",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "14",

}

TY - JOUR

T1 - Safety of nanoparticles in medicine

AU - Wolfram, Joy

AU - Zhu, Motao

AU - Yang, Yong

AU - Shen, Jianliang

AU - Gentile, Emanuela

AU - Paolino, Donatella

AU - Fresta, Massimo

AU - Nie, Guangjun

AU - Chen, Chunying

AU - Shen, Haifa

AU - Ferrari, Mauro

AU - Zhao, Yuliang

PY - 2015

Y1 - 2015

N2 - Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes. During the past two decades, a growing number of nanomedicines have received regulatory approval and many more show promise for future clinical translation. In this context, it is important to evaluate the safety of nanoparticles in order to achieve biocompatibility and desired activity. However, it is unwarranted to make generalized statements regarding the safety of nanoparticles, since the field of nanomedicine comprises a multitude of different manufactured nanoparticles made from various materials. Indeed, several nanotherapeutics that are currently approved, such as Doxil and Abraxane, exhibit fewer side effects than their small molecule counterparts, while other nanoparticles (e.g. metallic and carbon-based particles) tend to display toxicity. However, the hazardous nature of certain nanomedicines could be exploited for the ablation of diseased tissue, if selective targeting can be achieved. This review discusses the mechanisms for molecular, cellular, organ, and immune system toxicity, which can be observed with a subset of nanoparticles. Strategies for improving the safety of nanoparticles by surface modification and pretreatment with immunomodulators are also discussed. Additionally, important considerations for nanoparticle safety assessment are reviewed. In regards to clinical application, stricter regulations for the approval of nanomedicines might not be required. Rather, safety evaluation assays should be adjusted to be more appropriate for engineered nanoparticles.

AB - Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes. During the past two decades, a growing number of nanomedicines have received regulatory approval and many more show promise for future clinical translation. In this context, it is important to evaluate the safety of nanoparticles in order to achieve biocompatibility and desired activity. However, it is unwarranted to make generalized statements regarding the safety of nanoparticles, since the field of nanomedicine comprises a multitude of different manufactured nanoparticles made from various materials. Indeed, several nanotherapeutics that are currently approved, such as Doxil and Abraxane, exhibit fewer side effects than their small molecule counterparts, while other nanoparticles (e.g. metallic and carbon-based particles) tend to display toxicity. However, the hazardous nature of certain nanomedicines could be exploited for the ablation of diseased tissue, if selective targeting can be achieved. This review discusses the mechanisms for molecular, cellular, organ, and immune system toxicity, which can be observed with a subset of nanoparticles. Strategies for improving the safety of nanoparticles by surface modification and pretreatment with immunomodulators are also discussed. Additionally, important considerations for nanoparticle safety assessment are reviewed. In regards to clinical application, stricter regulations for the approval of nanomedicines might not be required. Rather, safety evaluation assays should be adjusted to be more appropriate for engineered nanoparticles.

KW - Nanomedicine

KW - Nanoparticle

KW - Nanosafety

KW - Nanotoxicity

KW - Safety

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84945171361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945171361&partnerID=8YFLogxK

M3 - Review article

C2 - 26601723

AN - SCOPUS:84945171361

VL - 16

SP - 1671

EP - 1681

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 14

ER -